Medical Eligibility Criteria BMI Requirements (Same as In-Person): You qualify if: BMI 30 (obesity category), OR BMI 27 (overweight category) with at least one weight-related health condition Weight-Related Conditions: Type 2 diabetes or prediabetes Hypertension (high blood pressure) High cholesterol or dyslipidemia Obstructive sleep apnea Cardiovascular disease Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease Osteoarthritis worsened by weight Calculate Your BMI: BMI = (Weight in pounds / Height in inches) 703 Quick Reference: Age Requirements: Typically 18+ for adults Some medications approved for age 12+ (with parental consent) Contraindications (Cannot Prescribe If Present): Absolute Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy or planning pregnancy within 2 months Breastfeeding Previous severe allergic reaction to GLP-1 medications Relative Contraindications (May Preclude or Require Caution): History of pancreatitis Severe gastroparesis Active eating disorder (anorexia, bulimia) Severe kidney disease Active gallbladder disease Diabetic retinopathy (recent diagnosis) Medication Considerations May Require Dose Adjustments: Currently taking insulin On sulfonylureas (diabetes medications) Taking blood thinners (warfarin) Generally Compatible: Blood pressure medications Cholesterol medications Most antidepressants Thyroid medications Provider will review all current medications during consultation
The total value proposition is unmatched among the best peptide vendors
No prospective studies have been conducted in humans in controlled circumstances to demonstrate whether CYP450 polymorphisms lead to an increase or a decrease in paracetamol oxidation nor have there been studies demonstrating that CYP450 polymorphisms in humans increase or decrease the risk of paracetamol toxicity before or after an overdose
Our S-acetyl glutathione ingredients meet US Pharmacopeia standards
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J, SURMOUNT-OSA Investigators
